Tarsus Pharmaceuticals, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
CEOs and CFOs (Bobak Azamian and Jeffrey Farrow) certified as of November 3, 2026 that the Q3 2026 10-Q fairly presents financial condition and results, with no material weaknesses disclosed in internal controls or disclosure procedures. No substantive business changes, transactions, or financial data provided in these exhibit certifications.
Why this rating
Routine SOX certification exhibits; no material facts, transactions, or operational changes disclosed. Standard periodic compliance filing.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.